Select Bibliography

Filter by any of these (after searching):

Graham, D.

AUTHOR ABSTRACT DEADLINES

A meeting abstract must be submitted by the first or corresponding author to the Alliance Publications Coordinator (publications@AllianceNCTN.org) at least two weeks prior to the meeting abstract submission deadline. For detailed information about Alliance Publications guidelines, please refer to the policies, along with the author abstract deadlines.

There are 6 items

Gemcitabine (G) and irinotecan (CPT-11) as first-line therapy for carcinoma (ca) of unknown primary (CUP): An NCCTG phase II trial

Holtan, S. G. , Foster, N. R. , Erlichman, C. E. , Aubry, M. ... - ASCO - J Clin Oncol - 2008

Abstract - Primary - Primary - Experimental - NCCTG-N004E

Pregabalin for hot flashes in women: NCCTG trial N07C1

Loprinzi, C. L. , Qin, R. , Stella, P. J. , Rowland, K. M., Jr ... - ASCO - J Clin Oncol - 2009

Abstract - Primary - Primary - Symptom Inter - NCCTG-N07C1

North Central Cancer Treatment Group (NCCTG) N0432: phase II trial of docetaxel with capecitabine and bevacizumab as first-line chemotherapy for patients with metastatic breast cancer

Perez, E. A. , Hillman, D. W. , Dentchev, T. , Le-Lindqwister, N. A. ... - - Ann Oncol - 2010

Manuscript - Primary - Primary - Breast - NCCTG-N0432

Survival of patients (pts) treated with high-dose radiotherapy (RT) and concurrent chemotherapy for unresectable non-small cell lung cancer (NSCLC).

Schild, S. , Graham, D. , Hillman, S. , Vora, S. , Yolanda, G. ... - ASCO - J Clin Oncol - 2009

Abstract - Primary - Primary - Respiratory - NCCTG-N0028

Long-term Survival of Patients (pts) Treated with High-dose Radiotherapy(rt) and Concurrent Chemotherapy for Unresectable Non-small Cell Lung Cancer (nsclc)

Schild, S. , Hillman, S. , Graham, D. , Vora, S. , Garces, Y. ... - MSTO - J Thorac Oncol - 2012

Abstract - Primary - Long-Term-Followup - Respiratory - NCCTG-N0028

Translational correlates, including outcome for patients (pts) with ER-/PR-/HER2- (triple negative (TNeg)) disease from N0234, a phase II trial of gemcitabine and erlotinib for pts with previously treated metastatic breast cancer (MBC)

Thome, S. , Hobday, T. , Hillman, D. , Aubry, M. , Lingle, W. ... - - J Clin Oncol - 2007

Abstract - Secondary - Primary - Breast - NCCTG-N0234